#	Pagina
attuale pagina	/open-h2020/projects/208528/index.html

Opendata, web and dolomites

CMI2T IA SIGNED

Harmless Clostridium bacteria as a highly targeted, continuous delivery system for immunomodulatory anti-cancer drugs

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

CMI2T IA project word cloud

Explore the words cloud of the CMI2T IA project. It provides you a very rough idea of what is the project "CMI2T IA" about.

modification ia successful class company oncology skills associate personalised vitro pathogenic solution bacteria obtaining laboratory ranging proprietary human genetic microbiologist expanding innovation candidate venture performing cmi2t bacterial vehicle pharmaceuticals disciplinary line assays career though dtp hands anti dualtpharma 12 months preferably business drug team strategy establishing critically hire cancer expertise orally first tolerated responsible efficacy position market planning mission pipeline leverage perspective drugs genetics he clostridium tumour cell broaden immunotherapy treatment lack feasibility lines transferable lab potent dual

Project "CMI2T IA" data sheet

The following table provides information about the project.

Coordinator	DualTpharma Organization address address: OXFORDLAAN 55 city: MAASTRICHT postcode: 6229 EV website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Project website	http://www.dualtpharma.com
Total cost	115˙625 €
EC max contribution	115˙625 € (100%)
Programme	1. H2020-EU.2.3.2.2. (Enhancing the innovation capacity of SMEs)
Code Call	H2020-INNOSUP-02-2016
Funding Scheme	CSA
Starting year	2017
Duration (year-month-day)	from 2017-09-01 to 2018-08-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	DualTpharma DualTpharma Organization address address: OXFORDLAAN 55 city: MAASTRICHT postcode: 6229 EV website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (MAASTRICHT)	coordinator	115˙625.00

Map

Project objective

DualTPharma (DTP) is a new venture developing a highly-potent and proprietary line of targeted pharmaceuticals for personalised cancer treatment. Our mission is to broaden our current pipeline by developing a new class of dual drugs for cancer treatment which are well tolerated and can be taken orally.

This novel solution comprises the application of non-pathogenic Clostridium bacteria as a novel tumour delivery vehicle for anti-cancer drugs to increase immunotherapy efficacy. Even though DTP has a multi-disciplinary team available in the oncology field, we lack the required expertise and skills in the bacterial genetic field to test the feasibility and lead the development of this new line of R&D. Therefore, the goal of this project, CMI2T IA, is to hire an Innovation Associate with expertise in the bacterial genetic field for our company, to determine the feasibility of this novel solution. The successful candidate is preferably a microbiologist with an interest in bacterial applications in cancer treatment and with strong expertise in bacterial genetics. During the first 12 months, the innovation associate will be involved with both technical and business-related activities. (S)he will be responsible for establishing the new line of R&D, with activities ranging from establishing and managing a new lab to, planning research, to performing hands-on laboratory work. More specifically, the research activities will include genetic modification of bacteria, and performing in vitro efficacy assays on human cell lines. From a business perspective, the Innovation Associate will critically contribute to a market study and the development of a business strategy of the new business unit.

This position will open up new career opportunities for the Innovation Associate, by obtaining transferable skills in both the business and technical field, and will leverage DTP’s growth by expanding DTP’s drug pipeline with a very novel and promising cancer drug delivery candidate.

Deliverables

List of deliverables.
training program oncology	Documents, reports	2019-04-18 13:53:34
training program business aspects	Documents, reports	2019-04-18 13:53:32

Take a look to the deliverables list in detail: detailed list of CMI2T IA deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2014	John T. Heap, Jan Theys, Muhammad Ehsaan, Aleksandra M Kubiak, Ludwig Dubois, Kim Paesmans, Lieve Van Mellaert, Richard Knox, Sarah A. Kuehne, Phillipe Lambin, Nigel P. Minton Spores of Clostridium engineered for clinical efficacy and safety cause regression and cure of tumors in vivo published pages: , ISSN: 1949-2553, DOI: 10.18632/oncotarget.1761	Oncotarget 5/7	2019-04-14
2016	Alexandra Mowday, Christopher Guise, David Ackerley, Nigel Minton, Philippe Lambin, Ludwig Dubois, Jan Theys, Jeff Smaill, Adam Patterson Advancing Clostridia to Clinical Trial: Past Lessons and Recent Progress published pages: 63, ISSN: 2072-6694, DOI: 10.3390/cancers8070063	Cancers 8/7	2019-04-14
2015	Aleksandra M. Kubiak, Nigel P. Minton The potential of clostridial spores as therapeutic delivery vehicles in tumour therapy published pages: 244-254, ISSN: 0923-2508, DOI: 10.1016/j.resmic.2014.12.006	Research in Microbiology 166/4	2019-04-14

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CMI2T IA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CMI2T IA" are provided by the European Opendata Portal: CORDIS opendata.